Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
Cancer Letters|March 26, 2016
Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cellsChandrabose Karthikeyan, Ritu Malla, Charles R Ashby, et al.
Haematologica|October 17, 2009
Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidinDamien R Ashby, Daniel P Gale, Mark Busbridge, et al.
Kidney International|April 24, 2009
Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatmentDamien R Ashby, Heather E Ford, Katie J Wynne, et al.
Molecular Medicine (Cambridge, Mass.)|July 17, 2021
2-O, 3-O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1-compromised macrophage functionMao Wang, Alex G Gauthier, Thomas P Kennedy, et al.
Kidney International|February 13, 2009
Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal diseaseDamien R Ashby, Daniel P Gale, Mark Busbridge, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 20, 2006
SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drugAndrew C McCreary, Jeffrey C Glennon, Charles R Ashby, et al.
The International Journal of Biochemistry & Cell Biology|April 15, 2014
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistanceHui Zhang, Rishil J Kathawala, Yi-Jun Wang, et al.
Biochemical Pharmacology|May 5, 2009
Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its functionChun-ling Dai, Yong-ju Liang, Li-ming Chen, et al.
Biological Psychiatry|March 23, 2005
Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot studyHeather C Strasser, Jessica Lilyestrom, Ebony R Ashby, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 21, 2007
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivoMark J Millan, Per Svenningsson, Charles R Ashby, et al.
Pageof 32